1. Annual Report 2025
  2. Research
  3. DAP_CAT

DAP_CAT

Epidemiological Research Group on Diabetes from Primary Care

The research team is made up of professionals from various disciplines and we focus our research on the study of diabetes and its complications, both in hospitals and primary care. The group has demonstrated a great ability to generate projects and publications in recent years.

The group's main lines of research are twofold: a) Complications of diabetes: atherosclerosis and microvascular disease, as the main causes of morbidity and mortality b) Epidemiology of diabetes: research in primary care and use of large databases. In recent years, the group has developed projects using the SIDIAP database on different aspects of diabetes in real-world evidence.

The group is a pioneer at the Spanish level in this area, and has active collaborations with international groups. In the last 5 years, the group has published 312 articles, of which 171 are in Q1 (55%) and 47 in D1 (15%). The average Impact factor of articles is 6,552 and they have 11,190 citations.

Group projects​​​​​

  • La Retinopatia Diabètica com a predictor de la morbilitat cardiovascular i la mortalitat en pacients amb Diabetis tipus 2. ICS - Institut Català de la Salut. 2021-2025. IP: Joan Francesc Barrot de la Puente.

  • RECONECT@: CONexiones sociales para el bienestar emocional en REsidencias. 2022-2025. IP: Sònia Miravet Jiménez.

  • Projecte FIDES: Fragilitat i Diabetis, un Estudi de Seguiment. Fundacion REDGDPS. 2025-2028. IP: Maria Ramon Granés.

  • Privació socioeconòmica i maneig de la població amb diabetis tipus 2 a l'àmbit d'Atenció Primària de Catalunya. 2024-2027. IP: Maria Ramon Granés.

  • Prevalencia, incidencia, factores de riesgo y complicaciones relacionadas con la disfunción eréctil entre las personas con diabetes mellitus tipo 2 en la base de datos de atención primaria SIDIAP-Estudio epiDEDM2cat. 2023-2026. IP: Bogdan Vlacho Vlacho.

  • ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2. (PMP21/00102). Instituto de Salud Carlos III. 2021-2025. IP: Josep Franch Nadal.

  • Evolución de la enfermedad renal en las personas con DM2 según los valores iniciales de filtrado glomerular y el tratamiento antidiabético. Estudio epiERDM2.cat. (PI22/00989). Instituto de Salud Carlos III. 2023-2025. IP: Joan-Antoni Vallès Callol.

  • Estudio sobre la importancia de los primeros años después del diagnóstico de una diabetes mellitus tipo 2 sobre el grado de control metabólico, manejo del paciente, costes sanitarios y la carga económica asociada al tratamiento del paciente. Estudio HEBE-T2DM. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2026. IP: Josep Franch Nadal.

  • Estudio epidemiológico de caracterización del riesgo trombótico entre las personas con fibrilación auricular y diabetes mellitus. Estudio epiFADM.cat. 2024-2027. IP: Josep Franch Nadal.

  • Estudio de la epidemiología y la evolución de la Enfermedad Renal Crónica en las personas con DM2 respecto a la población no diabética. Estudio epiERC_DM2.cat. 2023-2026. IP: Josep Franch Nadal.

  • Estudi descriptiu de les característiques clíniques i l'abordatge terapèutic dels factors de risc cardiovascular al debut de la diabetis tipus 2 (DM2) en funció del sexe en una cohort d'atenció primària a Catalunya. 2022-2025. IP: Anna Mª Ramírez Morros.

  • Caracterizació de subgrups en la diabetes tipus 2 (T2DM) al diagnòstic, un pas necessari cap a la medicina de precisió en diabetes. Estudi COPERNICAN. (STARFIELD-23/2). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Josep Franch Nadal, Berta Fernandez Camins.

  • Biomarcadores séricos de fibrosis hepática y su efecto sobre la morbimortalidad en sujetos con factores de riesgo de esteatosis hepática metabólica: análisis poblacional de la base de datos SIDIAP. 2024-2027. IP: Bogdan Vlacho Vlacho.

  • Assessing the Predictive Power of BERT Models in Type 2 Diabetes: Specific Cause Mortality associated with Adherence to Glucose Lowering Treatment using real world data from Spain and the UK. Sociedad Española de Endocrinología y Nutrición (FSEEN). 2025-2028. IP: Dídac Mauricio Puente.

  • Aportacions de la genètica a la caracterització de una cohort de Medicina Personalitzada de Precisió en el moment del debut de la diabetis. (SLT021/21/000030). Generalitat Catalunya. 2022-2025. IP: Josep Franch Nadal.

  • A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs (EXCEED). IQVIA LTD. 2020-2025. IP: Josep Franch Nadal.

  • Clinical Assessment of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) as Add-On Therapy in Insulin-treated Patients with Type 2 Diabetes: Insights from Real-World Studies in Spain and the UK. Institut Recerca Hospital Santa Creu i Sant Pau. 2025-2028. IP: Bogdan Vlacho Vlacho.

  • La Retinopatia Diabètica com a predictor de la morbilitat cardiovascular i la mortalitat en pacients amb Diabetis tipus 2. ICS - Institut Català de la Salut. 2021-2025. IP: Joan Francesc Barrot de la Puente.

  • Grup de Recerca Epidemiològica en Diabetis des de l'Atenció Primària (DAP_CAT). (INTENS-23/6). ICS - Institut Català de la Salut. 2024-2026. IP: Elena Hernandez Boluda.

  • Grup de recerca epidemiológica en Diabetis des de l'Atenció Primària de Catalunya (DAP.cat). (SENIOR-19/2). ICS - Institut Català de la Salut. 2020IP: Josep Franch Nadal.

  • Cap a una Medicina Personalitzada de Precisió en l'atenció a la persona amb diabetis. (SLT042/25/000004). Generalitat Catalunya. 2025-2029. IP: Josep Franch Nadal.

Group publications

  • Cendrós V, Verdú Rotellar JM, Parra J, Muñoz MA, Domingo M, Franch J. Usefulness of the H2FPEF score in the diagnosis and prognosis of heart failure with preserved ejection fraction in primary care. Aten. Prim. 2025;57(12):103335-103335. PMID:41061642.

  • Choudhary P, Paldánius PM, Salter JE, Lazaro Pacheco D, Claramunt FXC. Use of a Miniaturized Near-Infrared Spectroscopy Device for Type 2 Diabetes Mellitus Screening: Pooled Analysis of the Pilot ANODE01 and ANODE02 Studies. J. Diabetes Sci. Technol. 2025; PMID:40219802.

  • Merino M, Maravilla Herrera P, Artola S, Escalada J, Pérez A, Remón J et al. Tight and early HbA1c control in patients with type 2 diabetes mellitus in Spain: quantifying the social value. Front. Public Health. 2025;131511108-1511108. PMID:40717941.

  • Lago Sampedro A, Oualla Bachiri W, Maldonado Araque C, Valdés S, González Molero I, Doulatram Gamgaram V et al. The Interactive Effects of Fruit Intake Frequency and Serum miR-484 Levels as Biomarkers for Incident Type 2 Diabetes in a Prospective Cohort of the Spanish Adult Population: The Di@bet.es Study. Biomedicines. 2025;13(1): PMID:39857744.

  • Oualla Bachiri W, Lago Sampedro A, García Escobar E, Maldonado Araque C, Doulatram Gamgaram V, García Vivanco M et al. Surfactant Protein D Mediates the Association Between Smoking and Type 2 Diabetes Mellitus Incidence in the Spanish Adult Population: Di@bet.es Study. J. Xenobiotics. 2025;15(6): PMID:41283421.

  • Cendros V, Domingo M, Navas E, Munoz MA, Bayes Genis A, Verdu Rotellar JM. Rehospitalization, mortality and associated variables in primary care patients with heart failure and preserved ejection fraction after first hospitalization. Int. J. Cardiol. Cardiovasc. Risk Prevention. 2025;25200391-200391. PMID:40160695.

  • Ranzani O, Pérez CM, Rubio R, Ramírez Morros A, Jimenez A, Vidal M et al. Primary SARS-CoV-2 exposure by vaccination or infection shapes immune responses to omicron variants among a Spanish cohort. Nat. Commun. 2025;17(1):863-863. PMID:41390560.

  • Pérez CM, Ruiz Rius S, Ramírez Morros A, Vidal M, Opi DH, Santamaria P et al. Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections. J. Infect. 2025;90(4):106473-106473. PMID:40113142.

  • Alonso SP, Colomo N, Lago Sampedro A, Maldonado Araque C, García Fuentes E, Gutiérrez Repiso C et al. Population-based national incidence of thyroid dysfunction in Spain. Sci Rep. 2025;16(1):3230-3230. PMID:41419981.

  • Alòs F, Romaguera M, Claramunt FXC, Orfila F, Mínguez DA, Puig Ribera A. Physical activity in the digital age: Challenges and opportunities for primary care. Aten. Prim. 2025;57(12):103301-103301. PMID:40494157.

  • Mauricio D, Gratacòs M, Franch Nadal J. Managing diabetes across female reproductive stages. Trends Endocrinol. Metab. 2025;36(5):403-417. PMID:40089417.

  • Barrot J, Caylà JA, Mata Cases M, Real J, Vlacho B, Franch Nadal J et al. Machine learning models for the prediction of COVID-19 prognosis in the primary health care setting. BMC Prim. Care. 2025;26(1):310-310. PMID:41087937.

  • Molinos Albert LM, Rubio R, Martín Pérez C, Pradenas E, Torres C, Jiménez A et al. Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic. Cell Reports. 2025;44(4):115498-115498. PMID:40173043.

  • Barranco Altirriba M, Rossell J, Alonso N, Weber RJM, Ortega E, Lloyd GR et al. Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes. Cardiovasc. Diabetol. 2025;24(1):152-152. PMID:40176064.

  • Muzurovic E, Haluzik M, Horváth L, Vlacho B, Mauricio D. Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease. Curr. Pharm. Design. PMID:40641020.

  • Muñoz MA, Cendrós V, Navas E, Verdú Rotellar JM, Barrot J, Franch J. Incidence of first hospitalization for heart failure in type 2 diabetes mellitus: A population-based cohort study in primary care. Prim. Care Diabetes. 2025;19(5):471-477. PMID:40764218.

  • Cendrós V, Domingo M, Navas E, Muñoz MÁ, Bayés Genís A, Verdú Rotellar JM. Impact of Sex on Rehospitalization Rates and Mortality of Patients with Heart Failure with Preserved Ejection Fraction: Differences Between an Analysis Stratified by Sex and a Global Analysis. J. Pers. Med. 2025;15(7): PMID:40710414.

  • Vlacho B, Julve J, Genua I, Fernández Camins B, Real J, Franch Nadal J et al. Hypertriglyceridemia and its relationship with all-cause mortality and pancreatitis: Results from a large retrospective clinical registry. J. Clin. Lipidol. 2025;19(4):922-930. PMID:40467441.

  • Barranco Altirriba M, Granado Casas M, Yanes O, Capellades J, Junza A, Franch Nadal J et al. Guanine and pregnenolone sulfate are associated with incident type 2 diabetes in two independent populations. Front. Endocrinol. 2025;161706886-1706886. PMID:41416067.

  • Kacha G, Highton PJ, Funnell MP, Gillies C, Onuwe T, Kumar N et al. Global guideline recommended target achievements in glycaemic, blood pressure, and lipid control in type 2 diabetes: An updated meta-analysis of 1,618,972 participants. Diabetes Res. Clin. Pract. 2025;230113001-113001. PMID:41248832.

  • Puig R, Rojo López MI, Julve J, Castelblanco E, Ponomarenko J, Amezqueta S et al. Fecal Short-Chain Fatty Acids to Predict Prediabetes and Type 2 Diabetes Risk: An Exploratory Cross-Sectional Study. Nutrients. 2025;17(18): PMID:41010528.

  • Guiriguet C, Bustos M, Cantenys R, Hermosilla E, Camús J, Medina M et al. Enhancing the follow-up for patients with type 2 diabetes mellitus using a proactive scheduling computer tool: A paired cohort study in primary care. Prim. Care Diabetes. 2025;19(3):334-340. PMID:40157873.

  • Roel E, Henderson E, Valmayor S, Porthé V, Asensio A, Ramírez Morros A et al. Effectiveness of CONFIVAC, an intervention to enhance paediatric nurses and paediatricians skills to promote vaccination: A mixed-methods cluster randomized trial. Vaccine. 2025;62127603-127603. PMID:40818260.

  • Schnell O, Almandoz J, Anderson L, Barnard Kelly K, Battelino T, Blüher M et al. CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc. Diabetol. 2025;24(1):187-187. PMID:40316962.

  • Lazarus JV, Agirre Garrido L, Miralles Sanchez JE, Manolas MI, Tacke F, Villela Nogueira CA et al. Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries. Liver Int. 2025;45(12): PMID:41194401.

  • Hernáez A, Camps Vilaró A, Polo Alonso S, Subirana I, Ramos R, de Cid R et al. Cohort profile: the CORDELIA study (Collaborative cOhorts Reassembled Data to study mEchanisms and Longterm Incidence of chronic diseAses). Eur. J. Epidemiol. 2025;40(5):581-599. PMID:40353978.

  • Antonio Arques V, Camins BF, Vlacho B, Barrot J, Pérez JN, Torre EM et al. Clinical characteristics and management of type 2 diabetes in primary care in Spain. SED2 Study. Endocrinol. Diabetes Nutr. 2025;72(4):501543-501543. PMID:40180835.

  • Barrot de la Puente J, Lopez Arpí C, Ramon Granes M, Escribà Planes M, Fernandez Camins B, Vlacho B et al. Chronic kidney disease screening in primary care: a descriptive analysis of the Girona Sud health region. BMC Prim. Care. 2025;26(1):409-409. PMID:41276836.

  • Castelblanco E, Salvador Miras I, Carbonell M, Gratacòs M, Traveset A, Correig E et al. Choroidal thickness as predictor of subclinical carotid atherosclerosis in adults with type 1 diabetes. Sci Rep. 2025;15(1):8360-8360. PMID:40069268.

  • Cea Soriano L, Moreno A, Calonge M, Rivas A, Pulido Manzanero J, Colchero MC et al. Changes in prescription patterns of antidiabetic medication in patients newly diagnosed with type 2 diabetes in Spain: an observational study. BMJ Open. 2025;15(9): PMID:40983582.

  • Mesa A, Franch Nadal J, Navas E, Mauricio D. Cardiovascular disease in women with type 1 diabetes: a narrative review and insights from a population-based cohort analysis. Cardiovasc. Diabetol. 2025;24(1):217-217. PMID:40399939.

  • Torres Méndez JK, Rojo López MI, Antentas M, Vendrell P, Ortega E, Alonso N et al. Association between dietary niacin intake and diabetic retinopathy in a Catalonian population: a cross-sectional study. Front. Nutr. 2025;121626379-1626379. PMID:41164367.

  • Bajramagic M, Battelino T, Cos X, Cote M, Cui NY, Forbes A et al. Artificial intelligence-driven clinical decision support systems to assist healthcare professionals and people with diabetes in Europe at the point of care: a Delphi-based consensus roadmap. Diabetologia. 2025;69(2):259-273. PMID:41247494.

  • Amigó N, Castelblanco E, Julve J, Martínez Micaelo N, Alonso N, Hernández M et al. Advanced serum lipoprotein and glycoprotein profiling for cardiovascular event prediction in type 2 diabetes mellitus: the LIPOCAT study. Cardiovasc. Diabetol. 2025;24(1):88-88. PMID:39985069.

  • Voss EA, Yuan Z, Ali SR, Bosan R, Eworuke E, Brewster J et al. A study on the utilization of canagliflozin in type 1 diabetes mellitus using real-world data from four European countries. Diabetes Obes. Metab. 2025;27(9):5217-5224. PMID:40605139.

  • Segura Bayona C, Vidal Alaball J, Ramírez Morros A, Miró Catalina Q, Ruiz Comellas A. A Primary Care Program Based on Behavioral Reeducation and Abdominal Massage for Improving the Symptoms of Chronic Constipation: Protocol for a Randomized Controlled Trial. JMIR RES. Protoc. 2025;14PMID:41343762.

  • Henderson E, Valmayor S, Porthé V, Asensio A, Bruna X, Elizondo Alzola U et al. A mixed methods study protocol for CONFIVAC, an intervention to enhance paediatric nurses' and paediatricians' skills to promote vaccination and vaccine confidence. Vaccine: X. 2025;24

  • Navarro Cerdán JR, Pons Suñer P, Arnal L, Arlandis J, Llobet R, Perez Cortes JC et al. A machine learning approach for type 2 diabetes diagnosis and prognosis using tailored heterogeneous feature subsets. Med. Biol. Eng. Comput. 2025;63(9):2733-2752. PMID:40198441.

  • Manzini E, Vlacho B, Franch Nadal J, Escudero J, Génova A, Reixach E et al. A deep attention-based encoder for the prediction of type 2 diabetes longitudinal outcomes from routinely collected health care data. Expert Syst. Appl. 2025;274.

Proceeding Papers

  • Paldánius PM, Cos X, Lazaro Pancheco D, Salter J, Mauricio D. Non-invasive near-infrared system for screening for diabetes: the results from anode03. Diabetes Technol. Ther. 2025;27281-281.

  • Real J, Franch Nadal J, Mauricio D, Vlacho B, Carrasco M, Monroy G et al. Impact of ramadan on overdiagnosis of gestational diabetes: matched case-control analysis based on clinical registries. Gac. Sanit. 2025;39

  • Vinyoles E, Donatiu P, Tafalla M, Pelegrin M, Vanrell M, Soldevila N et al. Effect of music on home blood pressure self-measurements: a pragmatic pilot clinical trial. J. Hypertens. 2025;43(SUPPL 1)

  • Paldánius PM, Salter J, Choudhary P, Cos X, Mauricio D. Benefit: risk assessment of a novel non-invasive screening tool: insights from the anode clinical programme. Diabetes Technol. Ther. 2025;27153-154.

  • Paldánius PM, Salter J, Hernandez ME, Tipo B, Franch J, Cos X et al. Assessing implementation of novel diabetes screening methods across different care delivery settings. Diabetes Technol. Ther. 2025;27281-282.

Anar a l'inici